Allenic prostacyclins

Abstract

The present invention relates to allenic prostacyclin derivatives of the formula: ##STR1## wherein: n is 0, 1, 2 R.sup.1 is hydrogen, lower alkyl, lower hydroxyalkyl, or a pharmaceutically acceptable cation; R.sup.2 is hydrogen, lower alkyl, cycloalkyl, heteroalkyl, halogen, aryl, alkylthio, phenylthio, alkylsulfinyl, phenylsulfonyl, or trifluoromethyl, R.sup.3 is a lower alkyl, a cycloalkyl, phenyl, benzyl, a cycloheteroalkyl, a lower alkyl having one to eight carbons substituted with one or more fluorines or containing 1 or 2 unsaturated bonds; and carbon 15 may be in the R or the S configuration, or a mixture of R and S with the proviso that when R.sup.1 is a lower alkyl or lower hydroxyalkyl that carbon 15 is not in the R configuration. These compounds are useful for the treatment of platelet dysfunction and atherosclerosis. Also disclosed is the process for preparing these compounds and their appropriate intermediates.

Dependencies are inferred from the claim text.